110 related articles for article (PubMed ID: 25173558)
21. Molecular determinants of response to TRAIL in killing of normal and cancer cells.
Kim K; Fisher MJ; Xu SQ; el-Deiry WS
Clin Cancer Res; 2000 Feb; 6(2):335-46. PubMed ID: 10690508
[TBL] [Abstract][Full Text] [Related]
22. Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells.
Shiraishi T; Yoshida T; Nakata S; Horinaka M; Wakada M; Mizutani Y; Miki T; Sakai T
Cancer Res; 2005 Jul; 65(14):6364-70. PubMed ID: 16024639
[TBL] [Abstract][Full Text] [Related]
23. TRAIL, FasL and a blocking anti-DR5 antibody augment paclitaxel-induced apoptosis in human non-small-cell lung cancer.
Odoux C; Albers A; Amoscato AA; Lotze MT; Wong MK
Int J Cancer; 2002 Feb; 97(4):458-65. PubMed ID: 11802207
[TBL] [Abstract][Full Text] [Related]
24. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling.
Chen X; Kandasamy K; Srivastava RK
Cancer Res; 2003 Mar; 63(5):1059-66. PubMed ID: 12615723
[TBL] [Abstract][Full Text] [Related]
25. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs.
Ganten TM; Haas TL; Sykora J; Stahl H; Sprick MR; Fas SC; Krueger A; Weigand MA; Grosse-Wilde A; Stremmel W; Krammer PH; Walczak H
Cell Death Differ; 2004 Jul; 11 Suppl 1():S86-96. PubMed ID: 15105837
[TBL] [Abstract][Full Text] [Related]
26. A novel TRAIL mutant-TRAIL-Mu3 enhances the antitumor effects by the increased affinity and the up-expression of DR5 in pancreatic cancer.
Huang M; Zhu H; Yi C; Yan J; Wei L; Yang X; Chen S; Huang Y
Cancer Chemother Pharmacol; 2018 Nov; 82(5):829-838. PubMed ID: 30167846
[TBL] [Abstract][Full Text] [Related]
27. Death receptor 4 (DR4) efficiently kills breast cancer cells irrespective of their sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
Kazhdan I; Marciniak RA
Cancer Gene Ther; 2004 Oct; 11(10):691-8. PubMed ID: 15354201
[TBL] [Abstract][Full Text] [Related]
28. Phytosphingosine in combination with TRAIL sensitizes cancer cells to TRAIL through synergistic up-regulation of DR4 and DR5.
Choi SY; Kim MJ; Chung HY; Lee SJ; Jang YJ
Oncol Rep; 2007 Jan; 17(1):175-84. PubMed ID: 17143496
[TBL] [Abstract][Full Text] [Related]
29. 5, 7-Dimethoxyflavone sensitizes TRAIL-induced apoptosis through DR5 upregulation in hepatocellular carcinoma cells.
Yang JF; Cao JG; Tian L; Liu F
Cancer Chemother Pharmacol; 2012 Jan; 69(1):195-206. PubMed ID: 21660448
[TBL] [Abstract][Full Text] [Related]
30. Sensitization of melanoma cells for death ligand-induced apoptosis by an indirubin derivative--Enhancement of both extrinsic and intrinsic apoptosis pathways.
Berger A; Quast SA; Plötz M; Hein M; Kunz M; Langer P; Eberle J
Biochem Pharmacol; 2011 Jan; 81(1):71-81. PubMed ID: 20858462
[TBL] [Abstract][Full Text] [Related]
31. Irigenin sensitizes TRAIL-induced apoptosis via enhancing pro-apoptotic molecules in gastric cancer cells.
Xu Y; Gao CC; Pan ZG; Zhou CW
Biochem Biophys Res Commun; 2018 Feb; 496(3):998-1005. PubMed ID: 29305260
[TBL] [Abstract][Full Text] [Related]
32. TRAIL-induced apoptosis and expression of death receptor TRAIL-R1 and TRAIL-R2 in bladder cancer cells.
Szliszka E; Mazur B; Zydowicz G; Czuba ZP; Król W
Folia Histochem Cytobiol; 2009; 47(4):579-85. PubMed ID: 20430723
[TBL] [Abstract][Full Text] [Related]
33. Parthenolide sensitizes hepatocellular carcinoma cells to TRAIL by inducing the expression of death receptors through inhibition of STAT3 activation.
Carlisi D; D'Anneo A; Angileri L; Lauricella M; Emanuele S; Santulli A; Vento R; Tesoriere G
J Cell Physiol; 2011 Jun; 226(6):1632-41. PubMed ID: 21413021
[TBL] [Abstract][Full Text] [Related]
34. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand.
Mitsiades N; Poulaki V; Tseleni-Balafouta S; Koutras DA; Stamenkovic I
Cancer Res; 2000 Aug; 60(15):4122-9. PubMed ID: 10945619
[TBL] [Abstract][Full Text] [Related]
35. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis.
Lacour S; Hammann A; Wotawa A; Corcos L; Solary E; Dimanche-Boitrel MT
Cancer Res; 2001 Feb; 61(4):1645-51. PubMed ID: 11245478
[TBL] [Abstract][Full Text] [Related]
36. Construction and validation of a novel tumor necrosis factor-related apoptosis-inducing ligand mutant MuR5S4-TR.
Zhao Y; He J; Liu X; Yi C; Sun L; Zhu H
Asia Pac J Clin Oncol; 2024 Apr; 20(2):210-219. PubMed ID: 36658682
[TBL] [Abstract][Full Text] [Related]
37. Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-kappaB but is related to downregulation of initiator caspases and DR4.
Kurbanov BM; Fecker LF; Geilen CC; Sterry W; Eberle J
Oncogene; 2007 May; 26(23):3364-77. PubMed ID: 17160022
[TBL] [Abstract][Full Text] [Related]
38. A novel, soluble compound, C25, sensitizes to TRAIL-induced apoptosis through upregulation of DR5 expression.
James MA; Seibel WL; Kupert E; Hu XX; Potharla VY; Anderson MW
Anticancer Drugs; 2015 Jun; 26(5):518-30. PubMed ID: 25646742
[TBL] [Abstract][Full Text] [Related]
39. Repression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but not its receptors during oral cancer progression.
Vigneswaran N; Baucum DC; Wu J; Lou Y; Bouquot J; Muller S; Zacharias W
BMC Cancer; 2007 Jun; 7():108. PubMed ID: 17592646
[TBL] [Abstract][Full Text] [Related]
40. Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5.
Frese S; Frese-Schaper M; Andres AC; Miescher D; Zumkehr B; Schmid RA
Cancer Res; 2006 Jun; 66(11):5867-74. PubMed ID: 16740726
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
